Opinion
Video
Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer
Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones explores practical considerations for elacestrant with Callahan, Gradishar, and Vidal. The discussion covers challenges in testing patients in later lines of therapy, uncertainties in treating those with both ESR1 and PI3 kinase mutations, and the evolving prevalence of ESR1 mutations over time.
The segment also delves into the efficacy of elacestrant, with Gradishar discussing response rates and progression-free survival. Notably, real-world experiences align with trial results, highlighting the drug’s tolerability.
This concise summary provides practical insights into incorporating elacestrant into clinical practices, considering testing challenges, and aligning trial outcomes with real-world scenarios.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
